(Q36101382)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

review article

1 reference

title

Strategies for producing faster acting antidepressants (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Elena Castro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Pau Celada

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Analéa Bortolozzi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Angel Pazos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Francesc Artigas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 April 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

578-585

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15837601%20AND%20SRC:MED&resulttype=core&format=json

Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Current advances and trends in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Neurobiology of depression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Acute antidepressant effect following pulse loading with intravenous and oral clomipramine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

How does pindolol improve antidepressant action?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Pindolol Induces a Rapid Improvement of Depressed Patients Treated With Serotonin Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

PET-Determination of robalzotan (NAD-299) induced 5-HT(1A) receptor occupancy in the monkey brain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 1

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Modulation of serotonergic function in rat brain by VN2222, a serotonin reuptake inhibitor and 5-HT1A receptor agonist.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Serotonin receptors in the human brain--IV. Autoradiographic mapping of serotonin-2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Characterization and distribution of putative 5-ht7 receptors in guinea-pig brain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Effects of antidepressants on 5-HT7 receptor regulation in the rat hypothalamus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Serotonin and substance P co-exist in dorsal raphe neurons of the human brain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Neurokinin(1) receptor antagonists as potential antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Distribution of the substance P receptor (NK-1 receptor) in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Evaluation of the effect of chronic antidepressant treatment on neurokinin-1 receptor expression in the rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Antidepressants for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Antidepressant effects of ketamine in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

AMPA receptor potentiators for the treatment of CNS disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Characterization and functional significance of glucocorticoid receptors in patients with major depression: modulation by antidepressant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

The corticosteroid receptor hypothesis of depression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Rapid reversal of psychotic depression using mifepristone

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Hippocampal volume reduction in major depression.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Neurotrophins and depression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Small molecule Trk receptor agonists and other neurotrophic factor mimetics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Dopamine, depression and antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

The mesolimbic dopamine system as a target for rapid antidepressant action.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

Early onset of action of amineptine.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903398-2

7 January 2021